HealthEquity’s SWOT analysis: HSA leader’s stock poised for growth amid challenges

HealthEquity, Inc. (NASDAQ:HQY), a leading provider of Health Savings Accounts (HSAs) and related services, has been navigating a complex landscape of opportunities and challenges in recent months. With a market capitalization of $8.9 billion and an impressive revenue growth of 19.2% in the last twelve months, the company continues to solidify its position in the HSA market. According to InvestingPro data, HealthEquity maintains strong financial health with an overall score of 3.51 out of 5, indicating robust operational performance. Investors and analysts are closely watching its performance and future prospects.

Financial Performance and Market Position

HealthEquity has demonstrated strong financial performance in recent quarters, with consistent revenue growth and expanding profit margins. In its fiscal first quarter of 2026, the company reported revenue of $330.8 million, representing a 15% year-over-year increase. This growth was primarily driven by a 29% increase in custodial revenue, attributed to higher yields on HSA cash and robust HSA growth.

The company’s market position remains strong, with total HSA accounts reaching 9.89 million. While this figure fell slightly short of analyst estimates, it still represents significant growth in the HSA market. HealthEquity’s dominant market share and focus on technological innovation have positioned it well to capitalize on the increasing adoption of HSAs. The company’s solid financial foundation is evident in its current ratio of 4.06, indicating ample liquidity to meet short-term obligations. Want deeper insights? InvestingPro offers 10+ additional tips about HealthEquity’s financial health and growth prospects.

Leadership Transition and Strategic Direction

In a significant development, HealthEquity recently underwent a leadership change with the retirement of long-term CEO Jon Kessler after more than 15 years at the helm. Scott Cutler, previously CEO of StockX, has been appointed as his successor. This transition marks a new era for the company and has sparked interest among investors regarding potential shifts in strategy and direction.

The upcoming third-quarter earnings call, scheduled for December 9, 2025, will be particularly noteworthy as it will be Scott Cutler’s first event as CEO. Market observers will be keen to hear his vision for the company and any potential changes in strategic focus.

Legislative Landscape and Market Expansion

One of the most significant factors influencing HealthEquity’s future prospects is the potential for legislative changes that could expand the Total (EPA:TTEF) Addressable Market (TAM) for HSAs. Analysts have noted that developments such as the bipartisan HOPE Act (HR9394) and other HSA-friendly bills could increase the TAM by approximately 20 million households.

This potential market expansion has been a key driver behind analysts’ optimistic outlooks for HealthEquity. The company is well-positioned to capitalize on any legislative changes that broaden HSA eligibility or increase contribution limits.

Technological Innovation and Cost Management

HealthEquity has been focusing on technological innovations to improve user experience and reduce service costs. The company’s online, cloud-based platform has been a key differentiator in the market. Recent trends, such as a significant year-to-date spike in HQY app downloads, suggest that these efforts are paying off and could enhance security while potentially reducing fraud-related reimbursements.

The company has also been implementing measures to limit fraud on its platform, which has been a recent challenge. Management has expressed confidence in resolving these issues in the near term, with expectations for service costs related to fraud to normalize in the latter half of fiscal year 2026.

Financial Outlook and Guidance

HealthEquity has provided an updated financial outlook for fiscal year 2026, increasing the lower end of its revenue guidance to $1.285 billion - $1.305 billion. The company also raised its adjusted EBITDA outlook to $530 million - $550 million and increased its non-GAAP EPS guidance to $3.61 - $3.78. InvestingPro analysis shows that 8 analysts have recently revised their earnings estimates upward for the upcoming period, while the consensus recommendation stands at 1.43 (Strong Buy). Based on InvestingPro’s Fair Value analysis, the stock currently appears slightly overvalued. For more insights on market valuations, check out our overvalued stocks list.

Analysts project continued double-digit EPS growth over the next two years, driven by market share gains and higher yields on HSA cash. The company’s strong cash generation profile and potential for margin expansion have contributed to positive analyst sentiment.

Bear Case

How might persistent fraud-related expenses impact profitability?

HealthEquity has faced challenges related to fraud, which have resulted in increased service costs and impacted profitability. In fiscal Q4 2025, the company reported $17 million in incremental service costs related to fraud, causing adjusted EBITDA to fall short of expectations. These expenses are expected to persist into the first half of fiscal year 2026 before normalizing.

The ongoing fraud-related costs could put pressure on the company’s margins in the short term. Management has adjusted service gross margins down to approximately 20% in Q1 and 24% in Q2 of fiscal year 2026 to reflect these elevated costs. If these expenses continue longer than anticipated or increase in magnitude, it could negatively impact HealthEquity’s profitability and potentially lead to downward revisions in earnings estimates.

Could the CEO transition disrupt HealthEquity’s growth trajectory?

The recent transition from long-term CEO Jon Kessler to Scott Cutler represents a significant change in leadership for HealthEquity. While leadership changes can bring fresh perspectives and new strategies, they also carry inherent risks.

There is a possibility that the transition could lead to short-term disruptions in the company’s operations or strategic direction. The market may take a cautious approach until the new CEO’s vision and execution capabilities become clear. Additionally, any significant changes in corporate strategy or culture could potentially impact employee morale and productivity, at least in the short term.

Investors will be closely watching for signs of continuity in HealthEquity’s growth strategy and any potential shifts in focus under the new leadership. The success of this transition will be crucial in maintaining the company’s strong market position and growth trajectory.

Bull Case

How could potential legislative changes benefit HealthEquity’s market position?

Potential legislative changes present a significant opportunity for HealthEquity to expand its market reach and solidify its leadership position in the HSA industry. The bipartisan HOPE Act (HR9394) and other HSA-friendly bills under consideration could substantially increase the Total Addressable Market (TAM) for HSAs by approximately 20 million households.

If these legislative changes are enacted, HealthEquity, as a market leader, would be well-positioned to capture a significant portion of this expanded market. The company’s established infrastructure, technological capabilities, and strong brand recognition would give it a competitive advantage in attracting new customers from the newly eligible population.

Furthermore, legislative changes that increase HSA contribution limits or expand eligibility criteria could drive higher account balances and increased engagement with existing customers. This could lead to growth in custodial revenue, which has been a strong driver of HealthEquity’s recent financial performance.

What impact could increased HSA adoption have on the company’s financial performance?

Increased adoption of HSAs could have a substantial positive impact on HealthEquity’s financial performance. As more employers and individuals recognize the benefits of HSAs for managing healthcare costs and saving for future medical expenses, the demand for HealthEquity’s services is likely to grow.

Higher HSA adoption rates would likely lead to an increase in the number of accounts managed by HealthEquity, driving growth in service revenue. Additionally, as account balances grow over time, the company could see an expansion in its custodial revenue, which has been a key contributor to its recent strong financial results.

The trend towards higher-yielding investment options within HSAs could further boost HealthEquity’s profitability. As more account holders opt to invest a portion of their HSA balances, the company could benefit from increased fees associated with these investment services.

Moreover, as HealthEquity’s scale increases with higher HSA adoption, the company may be able to leverage its fixed costs more effectively, potentially leading to margin expansion and improved profitability over time.

SWOT Analysis

Strengths:

• Market leader in HSA services with a strong brand reputation
• Robust financial performance and consistent revenue growth
• Technological innovation driving improved user experience and operational efficiency
• Strong cash generation profile supporting strategic initiatives

Weaknesses:

• Recent challenges related to fraud and associated increased service costs
• Dependence on legislative environment for market expansion
• Potential short-term disruption due to CEO transition

Opportunities:

• Potential TAM expansion through favorable legislative changes
• Increasing adoption of HSAs driving market growth
• Technological innovations to enhance security and reduce fraud
• Cross-selling opportunities with complementary products and services

Threats:

• Competitive pressures in the HSA market from both established players and new entrants
• Regulatory changes that could negatively impact the HSA industry
• Macroeconomic factors affecting interest rates and investment returns
• Cybersecurity risks and potential data breaches

Analysts Targets

• JMP Securities (June 4th, 2025): $117.00
• Wells Fargo (NYSE:WFC) Securities (May 27th, 2025): $125.00
• RBC Capital Markets (May 22nd, 2025): $112.00
• Raymond (NSE:RYMD) James (March 25th, 2025): $115.00
• KeyBanc (March 24th, 2025): $110.00
• JMP Securities (March 19th, 2025): $110.00
• JMP Securities (January 24th, 2025): $120.00
• RBC Capital Markets (December 10th, 2024): $105.00
• JMP Securities (December 10th, 2024): $107.00
• Barclays (LON:BARC) (November 13th, 2024): $104.00

This analysis is based on information available up to June 13, 2025, and reflects the market conditions and analyst opinions as of that date. For the most comprehensive analysis of HealthEquity (HQY), including detailed financial metrics, Fair Value estimates, and expert insights, explore InvestingPro. The platform offers an extensive Pro Research Report, part of our coverage of 1,400+ top US stocks, providing actionable intelligence through intuitive visuals and expert analysis for smarter investing decisions.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on HQY. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore HQY’s full potential at InvestingPro.

Should you invest in HQY right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if HQY is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate HQY further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if HQY appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.